Enzymatic Deacylation of Teicoplanin Followed by Reductive Alkylation: Synthesis and Antibacterial Activity of New Glycopeptides.
作者:NANCY J. SNYDER、ROBIN D. G. COOPER、BARBARA S. BRIGGS、MILTON ZMIJEWSKI、DEBORAH L. MULLEN、RAYMOND E. KAISER、THALIA I. NICAS
DOI:10.7164/antibiotics.51.945
日期:——
Novel glycopeptides derived from teicoplanin were prepared and evaluated for activity against antibiotic-resistant Gram-positive pathogens. Removal of the fatty acid sidechains of teicoplanin was accomplished by enzymatic deacylation. The resulting deacylated teicoplanin was subjected to reductive alkylation resulting in mono- and di-alkylated compounds at the 2 possible primary amines. Deacylated teicoplanin was less active than teicoplanin against enterococci and staphylococci (MIC ≥32 μg/ml). All mono- and di-alkylated products regained some activity, and some had potent activity against both staphylococci and glycopeptide-resistant enterococci. MICs of the most potent di-alkylated compounds ranged from 0.25∼2 μg/ml against glycopeptide-resistant enterococci.
由替考拉宁衍生的一系列新型糖肽被制备出来,并评估了它们对耐抗生素的革兰氏阳性病原体的活性。通过酶促去酰化作用去除了替考拉宁的脂肪酸侧链。得到的去酰化替考拉宁经还原烷基化处理,在两个可能的初级氨基位点形成了单烷基化和双烷基化化合物。去酰化替考拉宁对肠球菌和葡萄球菌的活性低于替考拉宁(最低抑制浓度MIC ≥32 μg/ml)。所有单烷基化和双烷基化产物恢复了部分活性,其中一些对葡萄球菌和糖肽耐药性肠球菌表现出强大的活性。最具活性的双烷基化化合物的最低抑制浓度MIC范围为0.25∼2 μg/ml,针对糖肽耐药性肠球菌。